Search Results
Your search for ,had matches 18492 pages
Showing 16351 - 16400Increased Risk of Second Nonmelanoma Skin Cancer Among Patients Receiving Immunosuppressive Therapy
Patients with rheumatoid arthritis treated with methotrexate had an increased risk of a second nonmelanoma skin cancer, and adding anti–tumor necrosis factor (TNF) may increase that risk, according to results of a retrospective cohort study reported in JAMA Dermatology. A similar association was...
Shift in Treatment Patterns of Ductal Carcinoma in Situ
An evaluation of national treatment trends for ductal carcinoma in situ from 1991 to 2010 and their impact on survival revealed “a substantial shift in locoregional treatment patterns for ductal carcinoma in situ,” Mathias Worni, MD, of Duke University Medical Center, Durham, North Carolina, and...
Starting Over
My diagnosis of pleural mesothelioma early in 2015 couldn’t have been more surprising. In one day, I went from being a healthy, vibrant woman with a busy career and the excitement of launching a promising new business venture to a woman facing the greatest challenge of her life. The fact that my...
The Sixth Edition of the Essential Breast Cancer Book
Bookmark Title: Dr. Susan Love’s Breast Book Author: Susan M. Love, MD Publisher: Da Capo Lifelong Books Publication date: September 8, 2015 Price: $24.00; paperback, 704 pages For more than 25 years, Dr. Susan Love’s Breast Book has been the best source of information for women with breast...
Integrating Spirituality Into Palliative Care Services
Over the past couple of decades, the oncology community has made great strides in mediating the psychosocial needs of our patients. However, a patient’s spirituality is a subjective and uncomfortable issue for many oncologists, which leaves a gap in the continuum of care. To reach a better...
Selective Internal Radiation Therapy Impacts Liver Metastases in Colorectal Cancer
A novel interventional approach to treating liver metastases associated with colorectal cancer improved control of liver metastases, according to the SIRFLOX study presented at the 2015 ASCO Annual Meeting.1 The addition of selective internal radiation therapy to first-line chemotherapy extended...
Expert Point of View: Martine Piccart, MD, PhD
Martine Piccart, MD, PhD, Professor of Oncology at the Université Libre de Bruxelles, Belgium, and President of the European Cancer Organisation, said she found it “distressing” to see such large variations in 5-year survival across European countries. “I would like to stress the fact that these...
You’ve Lived A Good Life
The ASCO Post is pleased to reproduce installments of the “Art of Oncology” as published previously in the Journal of Clinical Oncology (JCO). These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Yet Another Reason Why Dogs Are Our Best Friends
BookmarkTitle: Heal: The Vital Role of Dogs in the Search for Cancer CuresAuthor: Arlene WeintraubPublisher: ECW PressPublication date: October 13, 2015Price: $16.95; paperback, 240 pages Comparative oncology, a fairly recent addition to the ever-evolving world of cancer research, studies the...
Racial Issues on the Road to Medicine
BookmarkTitle: Black Man in a White Coat: A Doctor’s Reflections on Race and MedicineAuthor: Damon Tweedy, MDPublisher: Picador, Macmillan PublishingPublication date: September 8, 2015Price: $26.00; hardcover, 304 pages Strained race relations over issues whose foundation is based on inequality...
The Highs and Lows of a Transplant Surgeon
Bookmark Title: Last Night in the OR: A Transplant Surgeon’s OdysseyAuthor: Bud Shaw, MDPublisher: Plume, division of Penguin GroupPublication date: September 15, 2015Price: $16.00; paperback, 304 pages Surgery has a distinct place in medicine. Surgeons cut deep into our bodies amid clusters of...
Ixazomib in Previously Treated Multiple Myeloma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On November 20, 2015, ixazomib (Ninlaro) was approved by the U.S....
Daratumumab in Previously Treated Multiple Myeloma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On November 16, 2015, daratumumab injection (Darzalex) was...
Parotid Tumor Excision, Albumen Print, Paris, February 1872
A Century of Progress The text and photographs on this page are excerpted from a four-volume series of books titled Oncology Tumors & Treatment: A Photographic History, by Stanley B. Burns, MD, FACS. The photos below are from the volume titled “The Anesthesia Era 1845-1875.” To view additional...
Osimertinib for Metastatic EGFR T790M–Mutant Non–Small Cell Lung Cancer After EGFR Inhibitor Therapy
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On November 13, 2015, osimertinib (Tagrisso) was granted...
Lung Cancer: Hope From Science
The following essay by Paul A. Bunn, Jr, MD, is adapted from The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful Stories, which was coedited by Stan Winokur, MD, and Vincent Coppola and published in May 2014. The book is available on Amazon.com and thebigcasino.org. I grew up...
A Swiss Psychotherapist Gives Her Perspective on Optimal Palliative Care
Over the past few decades, the oncology community has incorporated new evidence-based therapies to address the psychosocial needs of patients with cancer, especially those with advanced disease. To bring a global perspective to this evolving discipline, The ASCO Post recently spoke with Monika...
Foot Care in Oncology: The Cancer Patient From Ankle to Toe
There is as yet no clinical or research focus on foot complications that result from cancer therapies. Foot conditions, however, are common and have a considerable negative impact on patients’ ambulation, quality of life, and consistent dosing of antineoplastic agents.1-4 There are currently no...
The Complex Interactions of Treatment Costs, Clinical Outcomes, and Patient Expectations
A clinical dilemma that is receiving a great deal of attention in the oncology community is the undue financial burden some patients face during their treatment and into survivorship. While much emphasis is put on methods to reduce and help patients navigate the complex payment system, little is...
Cancer Care in Low-Resource Areas: Some Improvements Over the Years, but Serious Problems Remain
Low- and middle-income countries bear a larger share of the global cancer burden than does the developed world,” said Greta Massetti, PhD, Associate Director for Science, Centers for Disease Control and Prevention (CDC) Division of Cancer Prevention and Control and Co-Chair of the National Cancer...
Gut Bacteria May Facilitate Efficacy of Anti–PD-L1 Agents
Could the manipulation of bacteria in the gut pack the same punch in melanoma as antibodies targeting the programmed cell death protein and its ligand (PD-1/PD-L1)? It’s possible, at least in mice, according to research from the University of Chicago, recently published in Science.1 The researchers ...
Making a Difference for Patients: An Interview With Dr. Daniel F. Hayes, 2015–2016 President-Elect
Daniel F. Hayes, MD, FASCO, began his term as ASCO President-Elect this past June, and will serve as President in 2016–2017. A breast cancer specialist, he is Professor of Internal Medicine, the Stuart B. Padnos Professor in Breast Cancer, and the Clinical Director of the Breast Oncology Program at ...
NCCN Foundation Appoints Three New Representatives to Board of Directors
The National Comprehensive Cancer Network (NCCN) Foundation has appointed three new representatives to its Board of Directors: Heather Kopecky, PhD, MBA; Marc Samuels, JD, MPH; and Susan Stein, MPH. There are currently 15 members of the Board of Directors, responsible for the strategic direction...
Nodal Irradiation in Node-Positive Breast Cancer: It Is Not Time to Change Practice
Management of the regional nodes in breast cancer has evolved from the era of the extended radical mastectomy to exclusion of axillary dissection in appropriately selected patients. Throughout this evolution, studies of nodal irradiation have been shown to improve locoregional control, usually...
Regional Nodal Irradiation in Early Breast Cancer Yields Significant Disease-Free Survival Benefit in Two Trials
Two phase III trials recently reported in The New England Journal of Medicine indicated that the addition of regional nodal irradiation was associated with no or marginal overall survival benefit but significantly improved disease-free survival in patients with early-stage breast cancer.1,2 NCIC...
Nivolumab Improves Overall Survival vs Docetaxel in Advanced Previously Treated Squamous Cell NSCLC
In a phase III trial reported in The New England Journal of Medicine, Julie Brahmer, MD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, and colleagues found that treatment with the programmed cell death protein 1 (PD-1) immune checkpoint inhibitor antibody nivolumab...
Closing the Racial Survival Disparity Gap in Breast Cancer: Models for Change From Chicago, New York, and Beyond
It has long been said that white women of European ancestry are more likely to be diagnosed with breast cancer, but African American women are more likely to die of it. This statement has introduced multiple articles on the topic of the racial survival disparity in breast cancer, including our own...
Reducing Racial Disparities in Breast Cancer Incidence and Mortality Trends to Improve Outcomes
A recent report by DeSantis and colleagues from the American Cancer Society, summarized in this issue of The ASCO Post, presented breast cancer incidence and mortality data from an extensive analysis of the U.S. system of state-based tumor registries.1 The data showed that the incidence of breast...
Convergence of Breast Cancer Incidence but Continued Divergence of Mortality in Black Women and White Women
In an article published in CA: A Cancer Journal for Clinicians, Carol E. DeSantis, MPH, and colleagues from the American Cancer Society reported that the incidence of breast cancer in black women has caught up to that in white women, whereas the risk of mortality continues to be higher in black...
FDA Approves Necitumumab Combination for Metastatic Squamous NSCLC
The FDA approved necitumumab (Portrazza) in combination with gemcitabine and cisplatin for first-line treatment of patients with metastatic squamous non–small cell lung cancer (NSCLC). Necitumumab is not indicated for treatment of nonsquamous NSCLC. Necitumumab is a recombinant human IgG1...
Cobimetinib in BRAF-Mutant Unresectable or Metastatic Melanoma in Combination With Vemurafenib
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs On November 10, 2015, the U.S. Food and Drug Administration...
Trabectedin in Liposarcoma/Leiomyosarcoma: The Drug Is Approved, Now the Real Drug Development Begins!
Led by George Demetri, MD, of Dana-Farber Cancer Institute, Boston, expert medical oncology investigators from leading academic sarcoma centers and Janssen Pharmaceuticals employees performed a phase III trial in order to provide evidence for the U.S. Food and Drug Administration (FDA) approval of...
Improved Progression-Free Survival With Trabectedin vs Dacarbazine After Chemotherapy Failure in Liposarcoma or Leiomyosarcoma
In a phase III trial reported in the Journal of Clinical Oncology, George D. Demetri, MD, of Harvard Medical School and Dana-Farber Cancer Institute, Boston, and colleagues found that treatment with trabectedin (Yondelis) significantly improved progression-free survival vs dacarbazine in patients...
Molecularly Targeted Therapy Brings New Hope to Patients With Relapsed/Refractory Hairy Cell Leukemia
The treatment of hairy cell leukemia is one of the great success stories in hematologic malignancies, with patients now having a survival that is only slightly inferior to an age-matched normal population. Purine analogs, such as cladribine, are the mainstay of first-line therapy, with...
Nivolumab Receives Two FDA Approvals in November
Nivolumab (Opdivo) is a monoclonal antibody that binds to the programmed cell death protein 1 (PD-1) receptor and blocks its interaction with its ligands PD-L1 and PD-L2, releasing PD-1 pathway–mediated inhibition of the immune response. Late last month, the U.S. Food and Drug Administration (FDA)...
BRAF Inhibition Successful in Relapsed/Refractory Hairy Cell Leukemia
In two phase II studies reported in The New England Journal of Medicine, Enrico Tiacci, MD, of the University of Perugia, Italy, and colleagues found that the BRAF inhibitor vemurafenib (Zelboraf) produced responses in nearly all patients with BRAF V600E–positive hairy cell leukemia that relapsed...
The Best of SIO
The following five abstracts were chosen as the best studies presented at the 12th International Conference of the Society for Integrative Oncology (SIO) because of their quality and the impact they will have on the field of integrative medicine, according to Suzanna Zick, ND, MPH, Immediate Past...
Mind-Body Therapies Were the Focus at the 12th International Conference of the Society for Integrative Oncology
Among the highlights at the 12th International Conference of the Society for Integrative Oncology (SIO) was a 1-day joint meeting on acupuncture, oncology, and fascia cosponsored by SIO, the Society for Acupuncture Research, the Fascia Research Society, and the Osher Center for Integrative...
FDA Approves Elotuzumab in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has granted approval for elotuzumab (Empliciti) in combination with two other therapies to treat patients with multiple myeloma who have received one to three prior medications. “We are continuing to learn about the ways the immune system interacts with...
Ovarian Cancer: Current Treatment and Patient Management
Tough initial treatment decisions have “long-lasting ramifications and affect the entire treatment paradigm” for women with ovarian cancer, according to Bradley J. Monk, MD, FACS, FACOG, of the University of Arizona Cancer Center, Phoenix. In a true collaborative presentation at the Annual JADPRO...
Neoadjuvant Chemotherapy Appears to Have No Effect on Short-Term Outcomes in Breast Cancer Surgery
Patients who received neoadjuvant chemotherapy within 30 days prior to breast cancer surgery did not appear to be at increased risk for overall postoperative complications, according to a study presented at the 2015 Breast Cancer Symposium.1 “Although on unadjusted analysis there were more...
Tumor Profiling of Breast Tumors in Older Patients Reveals Differences From Those of Younger Patients
Using multiplatform profiling, researchers have identified potentially targetable biomarker aberrations in a large cohort of geriatric breast tumors.1 According to the study, presented at the 2015 Breast Cancer Symposium, these data may help researchers to design clinical trials focusing on...
Cancer Care Through Nonpharmacologic Symptom Management
Nonpharmacologic approaches to managing pain have a fairly robust base of science and research supporting their use but are not as widely accepted and understood as drug therapy in the realm of cancer care. In a breakout session at the 2015 Palliative Care in Oncology Symposium in Boston, experts...
Anamorelin Improves Cachexia Symptoms in Patients With Advanced Non–Small Cell Lung Cancer
The investigational agent anamorelin significantly increased lean body mass, body weight, total body mass, and fat mass in patients with advanced non–small cell lung cancer (NSCLC) and cachexia, according to Jennifer S. Temel, MD, who presented the results of two phase III studies at the 2015...
Olanzapine Significantly Reduces Chemotherapy-Induced Nausea and Vomiting
The addition of olanzapine to standard antiemetics significantly reduced chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, according to Rudolph M. Navari, MD, PhD, and colleagues. “As far as I know, this is the first trial that looked at no nausea as the ...
Filial Gaze at Our Noble Profession
As we stood outside patient X’s room going over the vitals, from a distance, I saw the father of the patient by the side of her bed. I saw him standing there and looking down at his child conveying what I guess were words of reassurance and reinforcing the pillars of strength needed for her...
FDA Oncology New Drug/New Indication Approvals for 2015
The following new hematology/oncology agents and expanded indications were approved by the U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research in 2015: Alectinib (Alecensa), an ALK inhibitor, for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive...
Mixing Metaphors to Change the Language of Cancer
BookmarkTitle: Malignant Metaphor: Confronting Cancer MythsAuthor: Alanna MitchellPublisher: ECW PressPublication date: September 15, 2015Price: $24.95; hardcover, 184 pages Illness is the night-side of life, a more onerous citizenship. Everyone who is born holds dual citizenship, in the kingdom...
Mohamed Bentires-Alj, PharmD, PhD, Honored With 2015 AACR Outstanding Investigator Award for Breast Cancer Research
Mohamed Bentires-Alj, PharmD, PhD, was recognized with the 8th Annual American Association for Cancer Research (AACR) Outstanding Investigator Award for Breast Cancer Research, funded by Susan G. Komen. He received the award at the 2015 San Antonio Breast Cancer Symposium. The AACR Outstanding...
AACR Recognizes Anne-Lise Børresen-Dale, DSc, With 2015 Distinguished Lectureship in Breast Cancer Research
Anne-Lise Børresen-Dale, DSc, Professor at the University of Oslo and Head of the Department of Genetics at the University Hospital Radiumhospitalet in Oslo, Norway, was honored with the 8th Annual American Association for Cancer Research (AACR) Distinguished Lectureship in Breast Cancer Research...
